Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBPhase 2b trial tests AP01, inhaled pirfenidone, in progressive PF. Avalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF).
New prototype therapy may repair IPF lung scarring by …
WEBApr 26, 2024 · Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports.
Study: ENV-101 improves IPF lung function, reverses fibrosis
WEBJun 7, 2024 · ENV-101 improved lung function and reversed key signs of lung scarring in patients with IPF, according to data from a Phase 2a trial.
IPF Update: FIBRONEER-IPF Study of Nerandomilast Meets …
WEB3 days ago · The FIBRONEER-IPF trial included 1177 participants with IPF across more than 30 countries. They were divided into 3 groups, taking a dose of nerandomilast 9 mg, nerandomilast 18 mg, or placebo twice daily. The primary end point was absolute change in FVC from baseline to week 52. 1. After 52 weeks, patients taking either dose of …
Nerandomilast Shows Promise in Idiopathic Pulmonary Fibrosis Trial
WEB5 days ago · IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind ...
Insilico Medicine reports positive Phase IIa | EurekAlert!
WEB4 days ago · Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI. Positive results ...
Experimental anticancer drug shows promise as treatment for …
WEBAug 23, 2022 · An experimental anticancer drug called saracatinib shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), a chronic and often fatal condition that causes scarring or fibrosis of the lungs and makes breathing difficult.
Newly Designed Molecule Is Promising Potential Therapy for …
WEBOct 28, 2022 · A team led by Kaminski used a newly designed molecule, called MRG-229, with potential therapeutic implications for IPF. The study is one of the first to use a microRNA mimic as a viable therapeutic in the lungs. The group published its findings October 17 in eBioMedicine.
Researchers identify new molecular target for idiopathic …
WEBMar 10, 2021 · Researchers have identified a new molecular target that could lead to new treatments for idiopathic pulmonary fibrosis (IPF), a deadly lung disease. IPF is characterized by severe scarring of the lungs, a condition called fibrosis, which makes it progressively difficult to breathe.
Study reveals potential to reverse lung fibrosis using the body's …
WEBApr 12, 2024 · Researchers are urgently trying to find ways to prevent or slow idiopathic pulmonary fibrosis (IPF) and related lung conditions, which can cause worsening shortness of breath, dry cough, and...